Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Clinical Effects of Esketamine Induction Intubation Versus Conventional Induction Intubation in ICU Patients: a Single-center Randomized Clinical Trial


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05464979

Organisation Name: Wuhan Union Hospital, China

Overal Status: Not yet recruiting

Start Date: August 1, 2022

Last Update: July 19, 2022

Lead Sponsor: Wuhan Union Hospital, China

Brief Summary: Intubation in the intensive care unit (ICU) is usually an emergency. Pathophysiological changes such as shock, respiratory failure, and metabolic acidosis in critically ill patients can significantly increase the incidence of adverse events during intubation.

Studies have shown that esketamine has no significant effect on body metabolism, endocrine system, liver, kidney, intestinal function and coagulation function. In terms of drug metabolism, esketamine has high bioavailability, short half-life, faster and more comfortable recovery of patients, and not only has the advantage of providing stable hemodynamics during endotracheal intubation, but also counteracts the respiratory depression caused by opioids. In addition, esketamine has antidepressant and anti-inflammatory properties. The investigators also found that combined prophylactic and therapeutic use of esketamine could attenuate systemic inflammation and inflammatory multi-organ injury in mice after CLP-induced lethal sepsis.

This project aims to study the clinical effect of esketamine induction intubation and conventional induction intubation in ICU patients.

Conditions:
  • Critically Ill Patients


Total execution time in seconds: 0.26297283172607